PIK3CA and cervical cancer: A comparison of the rate of PIK3CA mutations in 3q26-28 amplified and non-amplified cervical cancers disclosed no significant difference, with the amplified group harboring PIK3CA mutations in 26.3% of cases and the non-amplified group harboring such mutations in 27.3% of cases.